Wegovy (semaglutide) is a medication that helps with weight loss by mimicking a hormone that regulates appetite. It is prescribed to individuals with obesity or those with weight-related health problems. In the UK, Wegovy has been approved for NHS use for patients who meet certain criteria, providing a non-surgical option for those seeking medical weight-loss assistance.

The primary difference between mini gastric bypass surgery and a full gastric bypass is that the mini version of the surgery is performed in a modified manner that involves less intestinal rerouting and a shorter overall surgery time. After surgery, you should avoid nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin, Advil) and naproxen (Aleve). NSAIDs increase the risk of stomach ulcers. Patients who had gastric bypass surgery should avoid these medications indefinitely. Bread, Rice... +More

Although individual weight loss will fluctuate depending on factors like health, age, starting weight, and weight loss commitment, patients can expect to lose anywhere from five to 15 pounds per week for the first few months. At around the six-month mark, the weight loss will slow to one to two pounds per week.

Gastric sleeve results are typically impressive, with patients losing 50-60% of their excess body weight within the first year. The surgery also leads to improvements in obesity-related conditions like diabetes, hypertension, and sleep apnea. Long-term success depends on the patient’s ability to maintain a healthy lifestyle post-surgery.

The "Slimming Pen" refers to injectable medications like Saxenda and Wegovy (semaglutide) that help with weight loss. These medications regulate hunger hormones, helping users feel fuller and eat less. They are prescribed for individuals who need additional support in managing their weight, especially when diet and exercise alone aren’t sufficient. They’re increasingly popular in the UK, with potential NHS coverage for certain patients.